Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
2.77
Dollar change
+0.12
Percentage change
4.53
%
Index- P/E- EPS (ttm)-0.62 Insider Own38.02% Shs Outstand37.96M Perf Week2.97%
Market Cap105.15M Forward P/E- EPS next Y-0.86 Insider Trans0.14% Shs Float23.53M Perf Month-8.58%
Income-19.38M PEG- EPS next Q-0.16 Inst Own10.62% Short Float0.90% Perf Quarter-4.15%
Sales0.00M P/S- EPS this Y-20.56% Inst Trans-10.64% Short Ratio5.03 Perf Half Y6.13%
Book/sh1.35 P/B2.06 EPS next Y-18.89% ROA-43.77% Short Interest0.21M Perf Year82.24%
Cash/sh1.39 P/C1.99 EPS next 5Y30.00% ROE-46.77% 52W Range1.46 - 4.75 Perf YTD-2.46%
Dividend Est.- P/FCF- EPS past 5Y4.28% ROI-37.73% 52W High-41.68% Beta1.68
Dividend TTM- Quick Ratio19.27 Sales past 5Y-20.00% Gross Margin- 52W Low89.73% ATR (14)0.20
Dividend Ex-Date- Current Ratio19.27 EPS Y/Y TTM-19.30% Oper. Margin0.00% RSI (14)45.32 Volatility12.02% 6.96%
Employees19 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.00
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q4.09% Payout- Rel Volume0.49 Prev Close2.65
Sales Surprise- EPS Surprise14.29% Sales Q/Q- EarningsMar 19 AMC Avg Volume42.27K Price2.77
SMA20-4.66% SMA50-4.58% SMA200-5.44% Trades Volume20,711 Change4.53%
Date Action Analyst Rating Change Price Target Change
Jun-22-23Upgrade Oppenheimer Perform → Outperform $7
Apr-09-21Initiated Oppenheimer Outperform $27
Feb-17-21Initiated ROTH Capital Buy $38
Oct-30-20Initiated Guggenheim Buy $16
Jul-08-20Initiated Maxim Group Buy $14
Apr-30-19Initiated Dougherty & Company Buy $8
Mar-05-19Initiated Lake Street Buy $9
Mar-25-24 10:00AM
Mar-19-24 09:53PM
04:15PM
Jan-29-24 04:13PM
Jan-22-24 08:23AM
02:56PM Loading…
Dec-04-23 02:56PM
Nov-15-23 12:15PM
Nov-14-23 10:54PM
02:53PM
Nov-13-23 04:28PM
Nov-09-23 08:25AM
Nov-06-23 08:23AM
Sep-12-23 08:13AM
Sep-06-23 08:35AM
Aug-31-23 09:40AM
09:19PM Loading…
Aug-15-23 09:19PM
Aug-14-23 04:13PM
Aug-08-23 08:32AM
Jul-18-23 08:30AM
Jun-26-23 08:30AM
Jun-21-23 08:39AM
08:15AM
May-30-23 08:29AM
May-17-23 01:50PM
May-16-23 09:38PM
May-15-23 04:28PM
May-13-23 09:23AM
May-08-23 08:50AM
Apr-11-23 08:41AM
Mar-31-23 04:29AM
04:30PM Loading…
Mar-28-23 04:30PM
Mar-20-23 04:17PM
Mar-13-23 08:00AM
Mar-06-23 08:30AM
Dec-31-22 08:02AM
Dec-04-22 07:04AM
Nov-09-22 04:15PM
Nov-07-22 08:32AM
Nov-02-22 12:00PM
Oct-31-22 08:32AM
Oct-26-22 04:30PM
Oct-14-22 09:49AM
Sep-14-22 08:30AM
Sep-06-22 04:10PM
Aug-10-22 05:20PM
Aug-04-22 08:12AM
Aug-01-22 04:32PM
Jul-21-22 04:31PM
03:50PM
Jul-14-22 07:05AM
Jul-07-22 07:37AM
Jul-06-22 04:41PM
May-25-22 04:15PM
May-07-22 09:05AM
May-04-22 04:32PM
Apr-28-22 08:15AM
Mar-14-22 04:45PM
Mar-08-22 08:13AM
Feb-04-22 05:52AM
Feb-02-22 08:43AM
Jan-25-22 08:43AM
Jan-05-22 08:40AM
Dec-13-21 08:23AM
Nov-21-21 03:13PM
Nov-17-21 08:23AM
Nov-10-21 04:35PM
Nov-09-21 04:07PM
Nov-08-21 08:35AM
Nov-04-21 08:30AM
Nov-03-21 11:13AM
Oct-18-21 08:30AM
Oct-08-21 07:52AM
Oct-04-21 01:00AM
Sep-30-21 08:45AM
Sep-28-21 08:45AM
Sep-27-21 12:11PM
12:00PM
08:45AM
Sep-14-21 10:51AM
Sep-13-21 08:32AM
Sep-07-21 04:30PM
Aug-18-21 11:12AM
Aug-11-21 04:30PM
Aug-05-21 08:12AM
Jul-28-21 04:28PM
Jul-15-21 04:15PM
Jul-14-21 06:11AM
Jun-29-21 09:14AM
06:58AM
May-26-21 08:30AM
02:18AM
May-17-21 08:54AM
May-06-21 06:15AM
May-05-21 04:28PM
Apr-28-21 04:04PM
Apr-22-21 08:16AM
Apr-20-21 09:25AM
Apr-05-21 08:14AM
Mar-27-21 05:30AM
Mar-11-21 05:15AM
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wambeke David J.Chief Business OfficerNov 16 '23Buy2.4620,00049,200527,114Nov 16 04:37 PM
Von Koch Thomas10% OwnerJun 23 '23Buy3.401,470,5884,999,9994,326,435Jun 27 04:11 PM
Giuffre Randall MichaelDirectorJun 23 '23Buy3.9165,000254,150360,355Jun 26 04:42 PM
Wambeke David J.Chief Business OfficerJun 23 '23Buy3.9138,364150,003507,114Jun 26 04:14 PM
Pilnik Richard D.DirectorJun 23 '23Buy3.9138,363149,999248,245Jun 26 04:03 PM
Pauls Dietrich JohnPresident and CEOJun 23 '23Buy3.9112,78749,99768,591Jun 26 04:34 PM
Semba Charles PaulingDirectorJun 23 '23Buy3.9112,78749,99729,943Jun 26 04:26 PM
Kellen ScottCFO and SecretaryJun 23 '23Buy3.9110,00039,10032,290Jun 26 04:21 PM
Wambeke David J.Chief Business OfficerApr 10 '23Buy1.60468,750750,000468,750Apr 11 05:40 PM